Menu
Search
|

Menu

Close
X

Seres Therapeutics Inc MCRB.OQ (NASDAQ Stock Exchange Global Select Market)

9.66 USD
-- (--)
As of 2:29 AM IST
chart
Previous Close 9.66
Open --
Volume --
3m Avg Volume 55,138
Today’s High --
Today’s Low --
52 Week High 17.33
52 Week Low 7.92
Shares Outstanding (mil) 40.51
Market Capitalization (mil) 482.91
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.88 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY17
29
FY16
19
FY15
0
EPS (USD)
FY17
-1.496
FY16
-3.104
FY15
-2.539
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
21.87
5.77
Price to Book (MRQ)
vs sector
5.48
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
11.21
16.52
LT Debt to Equity (MRQ)
vs sector
11.21
12.22
Return on Investment (TTM)
vs sector
-41.51
14.43
Return on Equity (TTM)
vs sector
-76.34
16.13

EXECUTIVE LEADERSHIP

Roger Pomerantz
Chairman of the Board, President, Chief Executive Officer, Since 2014
Salary: $564,500.00
Bonus: --
Eric Shaff
Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Since 2018
Salary: --
Bonus: --
John Aunins
Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing, Since 2012
Salary: --
Bonus: --
David Cook
Chief Scientific Officer, Executive Vice President - Research & Development, Since 2012
Salary: --
Bonus: --
Thomas DesRosier
Chief Legal Officer, Executive Vice President and Secretary, Since 2016
Salary: $243,750.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

200 Sidney St
CAMBRIDGE   MA   02139-4218

Phone: +1617.9459626

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.

SPONSORED STORIES